# A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

> **NCT03329950** · PHASE1 · COMPLETED · sponsor: **Celldex Therapeutics** · enrollment: 132 (actual)

## Conditions studied

- Melanoma
- Non-small Cell Lung Cancer
- Breast Cancer
- Gastric Cancer
- Renal Cell Carcinoma
- Ovarian Cancer
- Cholangiocarcinoma
- Bladder Urothelial Carcinoma
- Pancreatic Adenocarcinoma
- Colorectal Cancer
- Esophageal Cancer
- Hepatic Cancer
- Head and Neck Cancer
- Primary Peritoneal Cancer
- Fallopian Tube Cancer
- Other Solid Tumors
- Diffuse Large B-cell Lymphoma (DLBCL)
- Mantle Cell Lymphoma
- Indolent B-cell Lymphomas
- Non-Hodgkin Lymphoma
- Follicular Lymphoma
- Lymphoplasmacytic Lymphoma
- Waldenstrom's Disease
- Marginal Zone Lymphoma
- Mucosa Associated Lymphoid Tissue
- Small Lymphocytic Leukemia

## Interventions

- **DRUG:** CDX-1140
- **DRUG:** CDX-301
- **DRUG:** pembrolizumab
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT03329950
- **Lead sponsor:** Celldex Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-01
- **Primary completion:** 2022-09-13
- **Final completion:** 2022-09-13
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2024-03-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03329950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03329950, "A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03329950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*